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Background:  The EVEREST II High Risk Registry (HRR) is a single arm study that demonstrated the safety and one year clinical benefit of 
percutaneous MV repair with the MitraClip device (Abbott Vascular). Two year clinical outcomes are reported in this cohort.
Methods:  78 patients (mean STS score, 16%) were enrolled and underwent the MitraClip procedure. MitraClip devices were implanted in 96% 
of patients; 98% (44/45) of surviving patients have been followed through 24 months. Freedom from death was 76% and 62% at 1 & 2 years, 
respectively. All patients underwent an evaluation of multiple measures of clinical effectiveness including NYHA Functional Class, Quality of Life (SF-
36), left ventricular (LV) function, and re-hospitalization for congestive heart failure (CHF).
Results:  The 30 day safety and one year clinical benefit have been previously reported. Echocardiographic LV function data and NYHA Functional 
Class through 24 months on an ITT basis demonstrate sustained improvement in NYHA Class, MR reduction , reductions in LV measures and diastolic 
annular dimensions (table 1). A detailed review of the data through 24 months will be presented.
Conclusions:  The positive one year clinical outcomes were sustained through two years in high surgical risk patients with significant MR enrolled 
in the EVEREST II HRR.
Outcome Measure Baseline 12 months 24 months
MR ≤ 2+, % 1.3 (n=78) 77.8 (n=54) 87.8 (n=41)
NYHA I/II, % 10.3 (n=78) 74.1 (n=54) 85.7 (n=42)
LVEDV (ml) 166.5±50.7 (n=78) 139.7±42.6 (n=54) 134.8±37.2 (n=38)
LVESV (ml) 79.9±42.7 (n=78) 72.2±35.8 (n=54) 69.8±32.4 (n=38)
SLAD, diastole (cm) 3.8±0.4 (n=74) 3.6±0.3 (n=52) 3.5±0.4 (n=27)
SLAD, systole (cm) 3.2±0.4 (n=74) 3.0±0.4 (n=52) 3.3±0.4 (n=27)
